FOLLOW US

Pharmaceutical industry group Pharmaceutical Research and Manufacturers of America insist that the Federal Food, Drug and Cosmetic Act outlines a "rigorous and thorough" drug approval process. They caution that allowing the Fifth Circuit's ruling to stand could have catastrophic consequences, wreaking havoc in the pharmaceutical world and stymying innovation.

The Integrity of Science-Based Determinations at Stake

Congress members raise a poignant concern: "The perils of this unwarranted judicial intervention into science-based determinations can hardly be overstated." They underscore that researchers, healthcare providers, and patients rely on the integrity of a science-based drug approval process, and judicial interference threatens access to life-improving and life-saving drugs.

Abortion Pill Battle : Specific Grievances Emerge

Moreover, certain groups take issue with particular elements of the Fifth Circuit panel's decision. Nurse practitioner and physician associate organizations, for instance, call for a reversal, as the decision eliminates an FDA rule permitting advanced practice clinicians and other qualified practitioners to prescribe mifepristone, thus limiting women's healthcare access.

The Religious Coalition for Reproductive Choice raises a different concern. They contend that restricting access to medication abortions could infringe on the religious beliefs of some patients who view abortion as a "morally acceptable choice."

Abortion Pill Battle :  A Clash of Ethics

Finally, medical associations, including the American Medical Association and the American College of Obstetricians & Gynecologists, criticize the medical associations and individual doctors challenging the FDA's approval of mifepristone. They claim that the lawsuit prioritizes doctors' concerns over patients, a clear violation of medical ethics and practices.

"The claim of injury is unsupported for the myriad legal reasons set forth by petitioners," they argue.

The legal battle continues to unfold, with stakeholders on both sides deeply entrenched in their positions. The federal government is represented by Erica L. Ross, Charles L. McCloud, Michael S. Raab, and Cynthia A. Barmore, while Danco Laboratories is represented by a team from Hogan Lovells. Pharmaceutical industry group PhRMA is represented in-house, and Congress members are represented by a team from Skadden Arps Slate Meagher & Flom LLP. The medical associations are represented by legal experts from their respective organizations, as the abortion pill battle rages on.